Article
A Pan-Cancer Review of ALK Mutations: Implications for Carcinogenesis and Therapy.
Current cancer drug targets - 1 Jan 2015
Yau Nick Ka Ming, Fong Andrew Yuon, Leung Hiu Fung, Verhoeft Krista Roberta, Lim Qin Ying, Lam Wai Yip, Wong Ian Chi Kei, Lui Vivian Wai Yan
Abstract excerpt
The anaplastic lymphoma kinase (ALK) is a druggable target for cancer therapy. By and large, the oncogenic activation of ALK in human tumors is known to occur by gene rearrangement (e.g. EML4-ALK, NMP-ALK, etc.). Clinical use of ALK inhibitors for "ALK-rearranged" lung cancers has remarkably improved patient survival. To date, much has been known about ALK gene rearrangement in human carcinogenesis and its drug...
Topics
- Anaplastic Lymphoma Kinase
- Antineoplastic Agents
- Carcinogenesis
- Gene Amplification
- Gene Rearrangement
- Genome-Wide Association Study
- Humans
- Molecular Targeted Therapy
- Mutation
- Neoplasms